Literature DB >> 11571739

p27(kip1) immunoreactivity correlates with long-term survival in pleural malignant mesothelioma.

M Bongiovanni1, P Cassoni, P De Giuli, L Viberti, S Cappia, C Ivaldi, L Chiusa, G Bussolati.   

Abstract

BACKGROUND: Pleural malignant mesothelioma (PMM) is a rare and highly aggressive tumor, whose development is strictly related to occupational exposure to asbestos. The prognosis of PMM is generally poor (median survival, 4-12 months), but a few have a relatively long survival. The objective of this study was to evaluate the use of the cell cycle-related proteins p27(kip1) and MIB-1 as prognostic indicators of survival in PMMs.
METHODS: Of 621 PMMs, the authors selected 27 cases with a relatively long-term survival (> 24 months) and a control group of 36 PMMs having a shorter (usual) survival (< 24 months).
RESULTS: The expression of the p27(kip1) was significantly higher in the long-term survival group compared with the control (short survival) group (81.41% vs. 31.94%; P < 0.0001). The PMMs of epithelioid histotype had a significantly higher p27(kip1) immunoreactivity compared with those of biphasic type (59.24% vs. 38.94%; P = 0.02). In agreement with the data in the literature, the proliferative activity (as detected by MIB-1 immunoreactivity) was significantly higher in short than long survival PMMs (43.53% vs. 14.11%; P < 0.0001) and in the biphasic histotype than in the epithelioid type (43.19% vs. 26.02%; P = 0.006).
CONCLUSIONS: The combined expression of high/low p27(kip1) and low/high Ki-67 values identified with 100% specificity and sensitivity long versus short survivors. p27(kip1) represents a reliable additional predictive factor for PMMs and a useful marker to identify patients having a more favorable prognosis. Copyright 2001 American Cancer Society.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11571739     DOI: 10.1002/1097-0142(20010901)92:5<1245::aid-cncr1444>3.0.co;2-g

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  9 in total

1.  Targeted inhibition of multiple receptor tyrosine kinases in mesothelioma.

Authors:  Wen-Bin Ou; Christopher Hubert; Joseph M Corson; Raphael Bueno; Daniel L Flynn; David J Sugarbaker; Jonathan A Fletcher
Journal:  Neoplasia       Date:  2011-01       Impact factor: 5.715

Review 2.  A crosstalk imbalance between p27(Kip1) and its interacting molecules enhances breast carcinogenesis.

Authors:  Weiwei He; Xueting Wang; Longbang Chen; Xiaoxiang Guan
Journal:  Cancer Biother Radiopharm       Date:  2012-06-12       Impact factor: 3.099

3.  Identification of potential therapeutic targets in malignant mesothelioma using cell-cycle gene expression analysis.

Authors:  Solange Romagnoli; Ester Fasoli; Valentina Vaira; Monica Falleni; Caterina Pellegrini; Anna Catania; Massimo Roncalli; Antonio Marchetti; Luigi Santambrogio; Guido Coggi; Silvano Bosari
Journal:  Am J Pathol       Date:  2009-02-13       Impact factor: 4.307

4.  Prognostic significance of cyclooxygenase-2 (COX-2) and expression of cell cycle inhibitors p21 and p27 in human pleural malignant mesothelioma.

Authors:  A Baldi; D Santini; F Vasaturo; M Santini; G Vicidomini; M Pia Di Marino; V Esposito; A M Groeger; G Liuzzi; B Vincenzi; G Tonini; M Piccoli; F Baldi; S Scarpa
Journal:  Thorax       Date:  2004-05       Impact factor: 9.139

5.  Is survivin expression prognostic or predictive in malignant pleural mesothelioma?

Authors:  Julija Hmeljak; Nina Erčulj; Vita Dolžan; Jože Pižem; Izidor Kern; Viljem Kovač; Maja Cemažar; Andrej Cör
Journal:  Virchows Arch       Date:  2013-01-29       Impact factor: 4.064

Review 6.  Biomarkers for malignant pleural mesothelioma: current status.

Authors:  Laurent Greillier; Paul Baas; John J Welch; Baktiar Hasan; Alexandre Passioukov
Journal:  Mol Diagn Ther       Date:  2008       Impact factor: 4.074

7.  Expression of cancer-associated molecules in malignant mesothelioma.

Authors:  Ben Davidson
Journal:  Biomark Insights       Date:  2007-05-30

8.  Ki67 index is an independent prognostic factor in epithelioid but not in non-epithelioid malignant pleural mesothelioma: a multicenter study.

Authors:  B Ghanim; T Klikovits; M A Hoda; G Lang; I Szirtes; U Setinek; A Rozsas; F Renyi-Vamos; V Laszlo; M Grusch; M Filipits; A Scheed; M Jakopovic; M Samarzija; L Brcic; D Stancic-Rokotov; I Kern; A Rozman; G Dekan; W Klepetko; W Berger; T Glasz; B Dome; B Hegedus
Journal:  Br J Cancer       Date:  2015-01-29       Impact factor: 7.640

9.  Molecular resistance fingerprint of pemetrexed and platinum in a long-term survivor of mesothelioma.

Authors:  Oluf Dimitri Røe; Adam Szulkin; Endre Anderssen; Arnar Flatberg; Helmut Sandeck; Tore Amundsen; Sten Even Erlandsen; Katalin Dobra; Stein Harald Sundstrøm
Journal:  PLoS One       Date:  2012-08-08       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.